Address: Veterinärplatz 1, Building IA, 1210 Vienna,Austria
Tel: +43-1-25077-5904
Savira pharmaceuticals – located in Vienna, Austria – is focusing on the development of drugs for the treatment of influenza. Based on know-how and intellectual property from its co-founders, the European Molecular Biology Laboratory (EMBL) and the Vienna-based biotech company onepharm Research and Development GmbH, Savira will manage a focused portfolio of medicinal chemistry programs aiming at the identification of lead candidates and the development of efficacious and selective anti-influenza drugs.
Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.
Savira was founded by the EMBL, onepharm, private investors, and Savira‘s management team.
You previously worked as CSO for onepharm; what was the motivation for creating Savira? OS: When I was working at onepharm, the organization was focused on anti-influenza and anti-inflammatory drug…
Dr. Christoph Zielinski, head of the organizational unit of the Comprehensive Cancer Center of Vienna (CCC), a representative of the Austrian oncological community, provides an insight into the key activities…
Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a…
Dr. Andreas Windischbauer, president of the Austrian Association of Full-Line Pharmaceutical Wholesalers (PHAGO) discusses the organization’s role within the Austrian pharma industry, its current challenges, price pressures, competition, and future…
Christa Wirthumer-Hoche, head of the Austrian Medicines and Medical Devices Agency (AGES) and chair of the European Medicines Agency (EMA) management board, discusses the role of AGES within Austria, similarities…
Mogens Guldberg, general manager of Novo Nordisk Austria, the Danish global powerhouse focused on innovative diabetic treatments, provides a unique insight into the obstacles associated with launching innovative products in…
Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis…
Historically, Austria was the dominant political power in Central Europe under the Habsburg dynasty which ruled until World War I. Although the 20th century has been marked by significant shake…
Can you give a brief summary of how Intercell started, how it developed and where it stands today? Intercell was created in 1997 as a spinoff from Vienna University. From…
Let’s start by introducing our readers to the Austrian affiliate of Cegedim. Can you summarize Cegedim scope of activities and operations in Austria, as well as the structure of this…
In your opinion, what have been the most important developments of the healthcare market in Austria over the last three years? To start with, even though we are a national…
You have been with Grünenthal since 2004 and as the Austria Country Manager since June 2012. What were your initial goals when you took up the position and how have…
Can you give our readers a snapshot of the scope of Takeda’s operations and the organizational structure within Austria? Takeda in Austria is a top-ten player with a turnover of…
See our Cookie Privacy Policy Here
